NCT01498913View on ClinicalTrials.gov

Observational Study of NovoNorm® in Subjects With Diabetes

CompletedOBSERVATIONAL
Enrollment

5,841

Participants

Timeline

Start Date

August 30, 2001

Primary Completion Date

March 25, 2005

Study Completion Date

March 25, 2005

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

repaglinide

Prescription with NovoNorm® 0.5mg, 1mg or 2mg tablets according to product labelling in daily clinical practice at the discretion of the physician

Trial Locations (1)

137-920

Novo Nordisk Investigational Site, Seoul

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY